MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-04-2026
Ocugen EV/EBITDA Ratio 2011-2026 | OCGN
Annual EV/EBITDA Ratio Ocugen
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.65 | -8.34 | -0.0753 | 0.414 | -2.44 | 0.308 | -0.343 | 1.05 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.05 | -8.65 | -2.26 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
17.3 | $ 21.65 | 1.12 % | $ 1.01 B |  USA |
 |
I-Mab
IMAB
|
595 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
29.4 | $ 0.9 | -0.18 % | $ 6.62 M | China |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
4.22 K | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
-21.1 | $ 22.3 | 1.55 % | $ 3.7 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
-82.4 | - | -9.65 % | $ 45.9 M | USA |
 |
Galectin Therapeutics
GALT
|
-1.92 | $ 2.37 | 1.72 % | $ 151 M | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Heron Therapeutics
HRTX
|
-4.31 | - | - | $ 198 M | USA |
 |
ImmuCell Corporation
ICCC
|
23.1 | $ 8.25 | -1.26 % | $ 74.5 M | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
InflaRx N.V.
IFRX
|
-3.65 | $ 1.61 | 8.78 % | $ 152 M | Germany |
 |
Innate Pharma S.A.
IPHA
|
-6.65 | $ 1.4 | -0.71 % | $ 235 M | France |
 |
Allakos
ALLK
|
-1.56 | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Inventiva S.A.
IVA
|
-9.77 | $ 5.13 | -0.39 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
-0.625 | $ 0.28 | -27.77 % | $ 653 K | USA |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-5.59 | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
-0.476 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-1.56 | - | -39.0 % | $ 4.57 M | USA |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-0.158 | - | -13.39 % | $ 1.45 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-3.44 | $ 19.16 | -2.39 % | $ 1.03 B | Britain |
 |
Aridis Pharmaceuticals
ARDS
|
-0.807 | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
4.1 | - | - | $ 27.2 B | Germany |
 |
Avenue Therapeutics
ATXI
|
0.871 | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.546 | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
-7.26 | $ 4.1 | 0.49 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-4.86 | $ 23.42 | 0.69 % | $ 2.98 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
-1.38 | $ 1.42 | -1.39 % | $ 378 M | Britain |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
19.4 | $ 241.79 | 4.55 % | $ 4.42 B | USA |
 |
AstraZeneca PLC
AZN
|
76.5 | - | - | $ 96.9 B | Britain |
 |
Eli Lilly and Company
LLY
|
143 | - | - | $ 783 B | USA |
 |
AVROBIO
AVRO
|
0.957 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 2.92 | 0.34 % | $ 4.81 M | Israel |
 |
Esperion Therapeutics
ESPR
|
-2.15 | - | - | $ 399 M | USA |
 |
BioDelivery Sciences International
BDSI
|
8 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-208 | - | 0.49 % | $ 251 B |  Cayman-islands |